Net

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
星期四, 三月 7, 2024

HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Company,” “NCS,” “we” or “us”), a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies, today announced its results for the quarter and year ended December 31, 2023.

Key Points: 
  • Total revenues were $35.2 million for the quarter ended December 31, 2023, a decrease of 12% compared to the fourth quarter of 2022.
  • Gross profit was $12.3 million, or a gross margin of 35%, for the fourth quarter of 2023, compared to $15.6 million, or 39%, for the fourth quarter of 2022.
  • Other income was $0.4 million for the fourth quarter of 2023 as compared to $1.4 million for the fourth quarter of 2022.
  • Consequently, we reversed our previously recorded litigation provision of $40.8 million during the fourth quarter of 2023.

KP Tissue Releases Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期四, 三月 7, 2024

MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full year 2023 financial and operational results of KPT and Kruger Products Inc. (Kruger Products).

Key Points: 
  • MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full year 2023 financial and operational results of KPT and Kruger Products Inc. (Kruger Products).
  • Net income was $16.5 million in Q4 2023 compared to $16.0 million in Q4 2022, an increase of $0.5 million.
  • Revenue was $1,873.0 million in Fiscal 2023 compared to $1,681.4 million in Fiscal 2022, an increase of $191.6 million or 11.4%.
  • KPT will hold its fourth quarter conference call on Thursday, March 7, 2024 at 8:30 a.m. Eastern Time.

Methode Electronics, Inc. Reports Fiscal 2024 Third Quarter Financial Results

Retrieved on: 
星期四, 三月 7, 2024

CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting and power distribution applications, today announced financial results for the third quarter of fiscal 2024 ended January 27, 2024.

Key Points: 
  • CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting and power distribution applications, today announced financial results for the third quarter of fiscal 2024 ended January 27, 2024.
  • We plan to share an update on our business review when we report fiscal fourth quarter results in June.
  • Comparing the Automotive segment’s quarter to the same quarter of fiscal 2023,
    Net sales were $139.7 million, down from $176.5 million.
  • Comparing the Industrial segment’s quarter to the same quarter of fiscal 2023,
    Net sales were $107.1 million, up from $91.0 million.

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

Retrieved on: 
星期四, 三月 7, 2024

ET –

Key Points: 
  • ET –
    WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and highlighted recent corporate developments.
  • “2023 was an exceptional year of execution and results for EyePoint Pharmaceuticals.
  • Review of Results for the Fourth Quarter Ended December 31, 2023
    For the quarter ended December 31, 2023, total net revenue was $14.0 million compared to $10.5 million for the quarter ended December 31, 2022.
  • ET to discuss the results for the fourth quarter and year ended December 31, 2023 and recent corporate developments.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
星期四, 三月 7, 2024

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

The Honest Company Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Outlook

Retrieved on: 
星期三, 三月 6, 2024

Notably, gross margin saw sequential improvement across each quarter of the year as the Company’s Transformation Initiative improved gross margin by 930 basis points from the first quarter to the fourth quarter of 2023.

Key Points: 
  • Notably, gross margin saw sequential improvement across each quarter of the year as the Company’s Transformation Initiative improved gross margin by 930 basis points from the first quarter to the fourth quarter of 2023.
  • Therefore, the Company expects the following financial outlook for the full fiscal year 2024:
    Net revenue growth of low-to-mid single digit percentage.
  • Included in the revenue outlook is a softer first half of 2024 compared to the second half of 2024.
  • A webcast and conference call to discuss fourth quarter and full year 2023 results is scheduled for today, March 6, 2024, at 1:30 p.m. Pacific time/4:30 p.m. Eastern time.

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 三月 5, 2024

Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.

Key Points: 
  • Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.
  • Aquestive commenced dosing in December 2023 in the Phase 3 pivotal PK clinical study of Anaphylm.
  • Non-GAAP adjusted EBITDA loss was $2.8 million in the fourth quarter 2023, compared to a $9.6 million loss in the fourth quarter 2022.
  • During the fourth quarter 2023, the Company accessed capital net proceeds of $3.7 million under its "At-the-Market" (ATM) facility.

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
星期二, 三月 5, 2024

REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the fourth quarter and full year ended December 31, 2023.
  • At the American Association for Cancer Research (AACR) Special Conference on pancreatic cancer, Purple Biotech presented new potential PDAC biomarker data for CM24.
  • In February 2023, Purple Biotech acquired a platform of conditionally activated T cell and NK cell engagers that selectively activate immune response within the tumor microenvironment.
  • As of December 31, 2023, Purple Biotech had cash and cash equivalents and short-term deposits of $15.3 million, compared to $31.7 million on December 31, 2022.

NFI announces fourth quarter and full year 2023 results

Retrieved on: 
星期四, 二月 29, 2024

WINNIPEG, Manitoba, Feb. 29, 2024 (GLOBE NEWSWIRE) -- (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. ("NFI" or the "Company"), a leader in zero-emission electric mobility solutions, today announced its audited consolidated financial results for Fiscal 2023.

Key Points: 
  • Results noted herein are for the 13-week period ("2023 Q4”) and the 52-week period ("Fiscal 2023”) ended December 31, 2023.
  • The comparisons reported in this press release compare 2023 Q4 to the 13-week period ("2022 Q4") and Fiscal 2023 to the 53-week period ("Fiscal 2022") ended January 1, 2023.
  • Comparisons and comments are also made to the 13-week period (“2023 Q3”) ended October 1, 2023.
  • NFI generated $19 million in cash flows from working capital in the fourth quarter as higher vehicle deliveries lowered finished goods and work-in-progress inventory.

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on: 
星期四, 二月 29, 2024

WEST CHESTER, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Verrica recognized product revenue of $1.9 million in the fourth quarter of 2023.
  • Verrica reported a net loss of $24.6 million for the fourth quarter of 2023, compared to a $5.9 million net loss for the same period in 2022.
  • Selling, general and administrative expenses were $17.0 million in the fourth quarter of 2023, compared to $3.2 million for the same period in 2022.
  • Research and development expenses were $5.3 million in the fourth quarter of 2023, compared to $3.0 million for the same period in 2022.